Abbott Develops New Pedialyte® Hydration Solution to Help Support Immune Health

Because supporting the immune system is top of mind for many people, Abbott (NYSE: ABT) is launching a new Pedialyte formulation specifically designed with key nutrients to support immune health. Pedialyte with Immune Support was developed for consumers looking for key immune-supporting nutrients in their hydration solution. In addition to an optimal balance of electrolytes and glucose found in Abbott's Pedialyte rehydration products, Pedialyte with Immune Support includes prebiotics, vitamin B12, vitamin C, vitamin E, and zinc, which are nutrients specifically chosen because of their role in supporting the immune system.

More than 50 years ago, when Pedialyte's original formulations were created, the products were designed to help sick children recover from dehydration symptoms by delivering much-needed fluid and electrolytes to support recovery. But with a focus on rapidly growing hydration needs among consumers, including adults, Abbott leveraged its expertise in science-led nutrition innovation to expand its suite of products to address the evolving needs.

"At Abbott, everything we do is driven by consumers and their healthcare needs," said Daniel Salvadori , executive vice president of Abbott's nutrition business. "Understanding consumers' concerns this year, our team of nutrition scientists developed an advanced hydration formula with key nutrients designed to support the immune system, helping us show up for people when it matters most and provide the reliability they've counted on for so long."

Hydration is an often-overlooked element of overall health and can help during recovery from illnesses. Pedialyte with Immune Support is one of four new Pedialyte products designed to meet a variety of hydration needs and is easily found in the pharmacy department in retail locations or online.

"Making changes to our diets is a good way to get nutrients that support the immune system because about 70 percent of our immune system is in the digestive tract, making nutrition a critical aspect of immune health," said Barbara Marriage, nutrition science lead for pediatric nutrition at Abbott. "Drinking Pedialyte with Immune Support can help people recover from illness, helping to prevent dehydration while also adding immune-supporting nutrients to the diet."

Pedialyte's new formulas include:

  • Pedialyte with Immune Support , available in mixed berry and fruit punch, is a unique formulation with four key nutrients to support the immune system, including zinc, and vitamins B12, C and E.
  • Pedialyte Sport , available in new fruit punch and lemon-lime flavors, has three times the electrolytes and one-fourth the sugar of leading sports drinks[1] with five electrolytes, including sodium, potassium, magnesium, chloride, and phosphate, designed for everyday and elite athletes participating in rigorous training and exercise programs.
  • Pedialyte Organic , available in crisp lemon berry and grape, is designed to prevent mild to moderate dehydration, is USDA-certified organic with no artificial colors, flavors or sweeteners and includes zinc for immune support.
  • Pedialyte Electrolyte Water with Zero Sugar, an electrolyte water drink available in berry frost and fruit punch, contains 50% more electrolytes than leading sports drinks and electrolyte waters[2], zinc for immune support and three key electrolytes: sodium, chloride and potassium—all without sugar, artificial flavors or colors.

New Pedialyte products are available in one-liter bottles and/or powder pack options. Pedialyte Sport and Pedialyte Electrolyte Water with Zero Sugar are located in the sports nutrition aisle. Pedialyte Organic can be found with Pedialyte's traditional products in the children's aisle, and Pedialyte with Immune Support can be found in the pharmacy department. Abbott's full suite of Pedialyte products can be found in-store and online through most major retailers, including Walmart, Target and Amazon.

About Abbott:  
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

[1] Pedialyte Sport has 1380 mg sodium and no more than 14g sugar per liter; leading sports drinks have ~460 mg sodium and ~58 g sugar per liter
[2] 30 mEq sodium electrolytes per liter vs 20 mEq in leading sports drinks and electrolyte waters

Cision View original content: https://www.prnewswire.com/news-releases/abbott-develops-new-pedialyte-hydration-solution-to-help-support-immune-health-301191798.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

FN Media Group News Commentary - The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report , Grand View Research said that the global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to grow at a CAGR of 6.4% from 2025 to 2030. One of the main factors expected to fuel market expansion is the growing incidence of diabetes in older individuals and the rising prevalence of blindness caused by diabetes. The introduction of novel diagnostic technologies and treatments and the increased awareness are driving the market expansion. The report said: "Diabetes is a globally prevalent health concern. It can result in Diabetic Retinopathy (DR), which is caused by damage to the blood vessels in the retina. DR leads to blurred vision and vision loss in most cases. International Diabetes Federation estimates that 1 in 8 adults will be living with diabetes in 2050. It also states urbanization, an aging population, decreasing physical activity, and the growing prevalence of obesity are some of the key aspects contributing to the rise in type 2 diabetes. DR is a serious microvascular complication of type I and type II diabetes. It is often caused by prolonged high blood sugar levels that damage the blood vessels in the retina. It can progress to sight-threatening stages, which can cause blindness and visual impairment if not treated. According to a report published by the WHO, DR is responsible for 4.8% of the 37 million blindness cases in the world. The prevalence of this condition in the U.S. is expected to increase rapidly. Despite all the necessary measures adopted by the diabetic population, DR can lead to permanent blindness based on the disease stage and severity of the condition. Active healthcaretech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Novo Nordisk AS (NYSE: NVO), Insulet Corporation (NASDAQ: PODD), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×